PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Tissue Engineering Applications Extend Beyond Cell-Based Therapies Finds Frost & Sullivan - With the realization that technology can be developed from the body due to the presence of cell types that can grow in artificial medium, concerns about the cultivation of cells and assembling them to grow into organs have vaporized
Tissue Engineering Applications Extend Beyond Cell-Based Therapies Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2009/05/01 - With the realization that technology can be developed from the body due to the presence of cell types that can grow in artificial medium, concerns about the cultivation of cells and assembling them to grow into organs have vaporized.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Some functional organs that have been developed in vitro include heart, kidney, and skin types.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Advances in Replacement Organs and Tissue Replacement, finds that the scope of tissue engineering applications extends beyond typical cell-based therapies. The focus has shifted toward understanding organ formation that could substantially enhance the progress toward developing tissues and organs in vitro.

If you are interested in the study, which features an overview, summary, challenges, and latest coverage of advances in replacement organs and tissue replacement, please send an email to Christina Alfaro, Corporate Communications, at christina.alfaro[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

Advances in tissue engineering have come about mainly due to the need to control the shortage in organ supply and treat chronic wounds. As conventional wound-healing technologies relied on synthetic materials that required frequent replacement, there is a huge opportunity for tissue engineering technology that support the requirements of chronic wound healing.

"The future of tissue engineering lies in the fields of biomaterial scaffold applications (both static and resorbable) but more so in organ regeneration and cell-based applications," says Technical Insights Research Analyst Nandini Ishwarakrishnan. "This is because biomaterial applications will more or less serve a supportive function for tissue growth. Additionally, cell-based therapies and organ regeneration technology have the ability to offer organ substitutes and improved tissue layers to treat wounds of the skin and bone, creating a great market opportunity."

As the pace of research in biomaterial applications has outstripped that of cell therapy and organ regeneration, scientists in the tissue engineering space are working on enhancing the production of allogenic and stem cells through the development of bioreactor technologies. Such technological growth is vital to ensure the long-term application of the technology.

However, the use of cell therapy and organ regeneration to create synthetic organs comes with a set of challenges regarding increasing the scale of production, regulatory hurdles, and enhancing the proof of concept studies. More importantly, industry participants need to demonstrate the safety, quality and application of the technology in real time. Therefore, they are striving to establish clinical trial protocols and standard procedures for manufacturing.

"There are concerns regarding the application of skin graft, especially xenografts that could have serious impact on the histocompatibility of the tissue with the host," notes Technical Insights Research Analyst Bhuvaneashwar Subramanian. "Technically, this also remains a key challenge in terms of identifying the right kind of tissue that could be employed in case of injuries."

It is also crucial to associate tissue samples with the patient's blood groups to prevent any kind of immunogenic reactions and hence, companies provide immunosuppressants in most cases. Further, with allogenic sources, there exists considerable risk of infection by microbes.

"The best way to counter safety issues is to develop a set of industry-standard operating procedures and protocols that could be further segmented into research in cell-based therapies and biomaterial applications," observes Ishwarakrishnan. "Essentially, owing to variations in the practices across laboratories in the tissue engineering sector, there is bound to be some differences in the quality of the products that are generated and released."

Moreover, the lack of standard regulatory protocols is a reason for the longer time-to-market of several products. A set of standard regulatory principles that govern tissue engineering activity worldwide will hasten the process of tissue engineering, aiding progress in the field.

Advances in Replacement Organs and Tissue Replacement, a part of the Technical Insights subscription, provides an overview and outlook for tissue engineering technology. The study covers the biotechnology application and the drivers and challenges associated with the technology. Further, this research service includes detailed technology analysis and industry trends, evaluated following extensive interviews with market participants.

Technical Insights, a division of Frost & Sullivan, is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

Advances in Replacement Organs and Tissue Replacement / D12E

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Tissue Engineering Applications Extend Beyond Cell-Based Therapies Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Christina Alfaro 
210.247.3830 christina.alfaro[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)